DailyIQ
DailyIQ
Last updatedUpdating…

VRDN·Viridian Therapeutics, Inc.

$30.86
+0.38 (+1.25%)
After Hours
High
$30.96
Open
$30.24
Market Cap
3.35B
52W High
$35.00
Low
$29.81
P. Close
$30.86
P/E
-
52W Low
$10.10
Fwd P/E
-14.49
DailyIQ Est.
$44.78
Inst. Own.
49.0%
Short Interest
16.58%
Days to Cover
8.0
NewEarnings release, scored · filed Nov 4, 2026tone -5.4 vs prior release · 59 lines scoredSee the breakdown
Technical Score (1D)
10
BEARISH
News Sentiment
71
BULLISH
VRDN is lagging the universe on the 1D view, with a Technical Score of 10 and declining momentum. A score this low means the stock ranks among the weakest names in DailyIQ's coverage on 12-month momentum, excluding the most recent month. Sentiment at 71 is diverging from that weakness. RSI sits in overbought territory in the indicator breakdown, a separate reading from the rank. A close above $32.13 would be the first sign of improvement; $29.04 is the downside reference if selling continues. DailyIQ's indicator breakdown shows how individual readings such as RSI (overbought) and MACD (bullish) look right now. Those readings are context only and do not feed the Technical Score, which ranks VRDN's momentum against the rest of the universe.
LOW TARGET
$33 +6.9%
2 analysts
MEAN TARGET
$42 +36.7%
7 analysts
HIGH TARGET
$54 +74.9%
16 analysts
PRICE RANGE
$33.00 - $54.00
SB / B / H / S / SS
8/14/1/1/1
DAILYIQ EST.
$44.78 (+45.1%)
Bought (1Y)
0 shares
$0
Sold (1Y)
14,212 shares
$348K
Tousignant JenniferChief Legal Officer
Option Exercise10,000 shares2026-08-19
Tousignant JenniferChief Legal Officer
Sell10,000 shares2026-08-19
Tousignant JenniferChief Legal Officer
Option Exercise10,000 shares2026-08-19
Tousignant JenniferChief Legal Officer
Sell4,212 shares2026-08-19
Tripuraneni RadhikaChief Medical Officer
Option Exercise40,000 shares2026-08-14
52/ 100
Neutral / mixed
Overall: Neutral
✓Revenue growing year over year
✕Negative net margin
✕Negative operating cash flow
Net Margin
-483.6%
Revenue CAGR
23.8%
Current Ratio
12.65x
Debt / Equity
0.03x
Return on Equity
-47.4%

EPS

EstBeatMiss
$-1.09$-0.87$-0.66$-0.45$-0.24Q3'25Q3'26Q4'26
QtrEstActual+/−
Q4'26$-0.72 - -
Q3'26$-0.99$-0.81+18.0%
Q3'25$-0.94$-0.34+63.9%

Revenue

EstBeatMiss
$19M$34M$48M$63M$77MQ3'25Q3'26Q4'26
QtrEstActual+/−
Q4'26$49M - -
Q3'26 - $26M -
Q3'25 - $71M -

Market Data

VRDN Stock Snapshot

BEARISH10/100
$30.87+$0.01 (0.0%)
Market cap
3.35B
Day range
$29.81 – $30.96
News sentiment
71/100 · Bullish
Analyst target
$42.19 (+36.7%)
Consensus
Buy · 25 analysts
52-week range+205.6% off low · -11.8% from high
$10.10$35.00
Price $30.87 DailyIQ Est. $44.78

Momentum has rolled over on Viridian Therapeutics, Inc., which is what drives the bearish read. Thinner liquidity means moves can extend past what the fundamentals alone justify.

Behaviour On Record

What VRDN's own history says about today's numbers

Realized volatility (21d)
97.5% 75th pct
Below its peak
-98.5%
vs 200-day average
+40.7%
Up days (1y)
48%

Viridian Therapeutics, Inc. is currently running 97.5% annualised volatility over the last 21 sessions. Measured against VRDN's own 11 years of daily returns rather than a market-wide average, that is the 75th percentile — elevated for this stock, against a typical reading of 71.5%.

VRDN is trading -98.5% below its running peak. Across 10 full years on file, its median worst-drawdown-in-a-year was -71.6%, and the deepest was -90.9% in 2019. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began, and where past declines also continued.

Price sits +40.7% from its 200-day moving average. Against every other day in its history, that gap ranks at the 91st percentile — a wider gap than this stock usually carries. Over the past year VRDN closed higher on 48% of sessions, and it is currently 3 sessions into a falling streak.

On November specifically: over 12 years of records, VRDN finished the month higher 8 of 12 times, with a median return of +16.8% and an average of +12.8%. Its strongest month historically has been January at +19.5% on average, its weakest February at -14.5%.

Overnight risk is measurable too: VRDN has opened more than 2% away from the prior close in 775 of 2,804 sessions (27.6% of the time), with the largest gaps running +57.5% and -39.2%.

All figures computed from 2,808 daily closes between 2014-06-18 and 2026-11-13, split-adjusted, recomputed daily. Percentiles are against VRDN's own 12-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of VRDN's sector?

Viridian Therapeutics, Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (weakening). Within its narrower Biotechnology industry group, VRDN ranks 9th of 15 tracked industries, weakening.

Sector rank
#2 of 12
Sector state
Weakening
Sector rotation score
82
Industry rank
#9 of 15

Options Market

What is the options market pricing for VRDN?

CallsPuts

For Viridian Therapeutics, Inc.'s nearest expiry (2026-11-20, 5 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.00), with at-the-money implied volatility around 148.0%. The options market is pricing roughly a ±19.7% move by that expiry — a range of about $24.65–$36.77.

Put/call ratio (2026-11-20)
0.00
ATM implied volatility
148.0%
Total open interest
1,221
Expected move by 2026-11-20
±19.7% ($24.65–$36.77)

Analyst Consensus Estimates

What do analysts expect VRDN to earn?

Analysts expect Viridian Therapeutics, Inc. to earn -$3.92 per share in the fiscal year ending Dec 2026 and $2.00 in the fiscal year ending Dec 2029, from 2 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.

Quarter endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Sep 2026-$1.02-$1.26 to -$0.7812$5M14
Dec 2026-$0.95-$1.21 to -$0.7112$19M14
Mar 2027-$0.73-$0.78 to -$0.682--
Jun 2027-$0.59-$0.68 to -$0.492--
Sep 2027-$0.50-$0.58 to -$0.422--
Fiscal year endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Dec 2026-$3.92-$4.60 to -$3.4113$24M14
Dec 2027-$2.71-$4.10 to -$1.7013$238M14
Dec 2028$0.39-$2.87 to $3.642--
Dec 2029$2.00-$1.49 to $5.492--

Analyst Rating Changes

Are analysts turning bullish or bearish on VRDN?

Wedbush most recently reiterated its rating on Viridian Therapeutics, Inc. to Outperform on Nov 10, 2026 with a price target of $44 (from $42). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Wedbush: Outperform
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Nov 10, 2026WedbushMaintainedOutperform$42 → $44
Nov 10, 2026Wells FargoMaintainedOverweight$34 → $39
Nov 5, 2026RBC CapitalMaintainedOutperform$38 → $41
Nov 5, 2026Leerink PartnersMaintainedOutperform$50 → $54
Nov 5, 2026Truist SecuritiesMaintainedBuy$39 → $42
Nov 5, 2026Wells FargoMaintainedOverweight$31 → $34
Nov 5, 2026Evercore ISI GroupMaintainedOutperform$26 → $33
Nov 5, 2026WedbushMaintainedOutperform$41 → $42
Nov 5, 2026HC Wainwright & Co.MaintainedBuy$22 → $40
Nov 4, 2026NeedhamMaintainedBuy$34 → $38
Sep 22, 2026RBC CapitalMaintainedOutperform$36 → $38
Aug 7, 2026RBC CapitalMaintainedOutperform$35 → $36

Corporate Stakes

Which companies own a stake in VRDN?

0.09%held by MRK

Merck & Co., Inc. reports a stake in Viridian Therapeutics, Inc. on SEC Form 13F: 93.4K shares, about 0.09% of the company, worth $1.9M at the end of Q3 2026. At today's price that stake is worth $2.9M, about 0.00% of MRK's own market value.

Holder
MRK
Shares held
93.4K
Stake
0.09%
Value
$1.9M
HolderLast quarterShares% of VRDNValue at filingValue nowChange
Merck & Co., Inc. MRKUnchanged93.4K0.09%$1.9M$2.9M+49.9%

Form 13F lists US-listed shares held at quarter-end and is filed up to 45 days later. Stakes in private companies are not on it. Value now and Change put those same shares, adjusted for any stock split, at today's price against their reported quarter-end value, so they do not reflect buying or selling since.

Earnings Release, Scored

What did Viridian Therapeutics, Inc.'s latest earnings release say?

Filed Nov 4, 2026 · SEC Form 8-K, Exhibit 99

Tone56.3/ 100-5.4 vs prior release
Hedging words1.06per 100 words+0.95 vs prior release
Tone, last 3 releasesScale 50–73

Most important lines

  1. 1

    R&D Expenses: Research and development expenses were $70.1 million during the three months ended September 30, 2026, compared to $86.3 million during the three months ended September 30, 2025.

  2. 2

    In non-human primates, a single, high-dose of VRDN-008 showed a longer half-life and more sustained IgG reduction versus efgartigimod in a head-to-head study.

  3. 3

    Net Loss: Net loss for the three months ended September 30, 2026 was $101.2 million, compared with $34.6 million for the same period in 2025.

    Negative tone

ETF holders

ETFs holding VRDN

News & sentiment

What is the news saying about VRDN?

VRDN rose 65.0% over the month to Nov 13. News tone held between 50 and 100 from Oct 16 to Nov 2, then dropped to 16 on Nov 3.

Daily close and news tone, Oct 13 to Nov 13
$20$30Oct 13Oct 14Oct 15Oct 16: tone 100Oct 19Oct 20: tone 50Oct 21Oct 22Oct 23Oct 26Oct 27: tone 75Oct 28Oct 29Oct 30Nov 2: tone 75Nov 3: tone 16Nov 4: tone 61Nov 5: tone 73Nov 6: tone 64Nov 9: tone 71Nov 10: tone 73Nov 11Nov 12Nov 13Oct 13News toneNov 13123
  1. Oct 23 -11.9%
  2. Oct 26 +15.5%
  3. Nov 4 +18.2%same day: Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress

Technical analysis

How strong is VRDN's momentum right now?

On the daily chart VRDN ranks at the 10th percentile for momentum against 1,062 stocks and ETFs, a bearish reading.

Momentum rank by timeframe0 = weakest, 100 = strongest
See what drives the rankThe inputs behind each timeframe's momentum rank, plus RSI, stochastics, Bollinger Bands and moving averages. Free with an account.

Institutional ownership

Are big funds buying or selling VRDN?

33 of the 59 tracked managers added to VRDN in their latest 13F and 22 trimmed. Together they own 48.9% of the company, worth $1.1B. Fidelity and BlackRock alone hold 24.7%.

33adding22trimming4unchanged
Largest holders by stake, latest 13FBar = share of VRDN
  1. $360.5M positionAdded 43.2% last quarter
  2. $192.1M positionNew position last quarter
  3. $100.4M positionTrimmed 20.4% last quarter
  4. $97.9M positionAdded 3.9% last quarter
  5. $57.7M positionNew position last quarter
  6. $49.8M positionTrimmed 12.2% last quarter
  7. $36.1M positionAdded 8.8% last quarter
  8. $31.6M positionTrimmed 10.6% last quarter
  9. $20.0M positionTrimmed 12.5% last quarter
  10. $16.6M positionNew position last quarter
Full holdings history

Discover more

How has VRDN done against its peers?

Over the six months to Nov 13, VRDN returned +72.5%. Of the 15 related stocks and ETFs, 1 did better, led by MRNA at +345.8%.

Change since May 13, through Nov 13
−200%0%+200%+400%+600%May 13JulAugSepOctNov 13MRNA +345.8%VRDN +72.5%UTHR +2.0%